A trial design for evaluation of empiric programming of implantable cardioverter defibrillators to improve patient management by Morgan, John M et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Current Controlled Trials in 
Cardiovascular Medicine
Open Access Review
A trial design for evaluation of empiric programming of implantable 
cardioverter defibrillators to improve patient management
John M Morgan*1, Laurence D Sterns2, Jodi L Hanson3, Kevin T Ousdigian3, 
Mary F Otterness3 and Bruce L Wilkoff4
Address: 1Southampton General Hospital, Southampton, United Kingdom, 2Victoria Heart Institute, Victoria, BC, Canada, 3Medtronic, Inc., 
Minneapolis, MN, United States and 4Cleveland Clinic Foundation, Cleveland, OH, United States
Email: John M Morgan* - jmm@cardiology.co.uk; Laurence D Sterns - ldsterns@shaw.ca; Jodi L Hanson - jodi.l.hanson@medtronic.com; 
K e v i nTO u s d i g i a n-k e v i n . o u s d i g i a n@medtronic.com; Mary F Otterness - mary.otterness@medtronic.com; Bruce L Wilkoff - wilkofb@ccf.org
* Corresponding author    
Implantable cardioverter defibrillatorICDshocksprogrammingempiricdetectiontherapy
Abstract
The delivery of implantable cardioverter defibrillator (ICD) therapy is sophisticated and requires
the programming of over 100 settings. Physicians tailor these settings with the intention of
optimizing ICD therapeutic efficacy, but the usefulness of this approach has not been studied and
is unknown. Empiric programming of settings such as anti-tachycardia pacing (ATP) has been
demonstrated to be effective, but an empiric approach to programming all VT/VF detection and
therapy settings has not been studied. A single standardized empiric programming regimen was
developed based on key strategies with the intention of restricting shock delivery to circumstances
when it is the only effective and appropriate therapy. The EMPIRIC trial is a worldwide, multi-
center, prospective, one-to-one randomized comparison of empiric to physician tailored
programming for VT/VF detection and therapy in a broad group of about 900 dual chamber ICD
patients. The trial will provide a better understanding of how particular programming strategies
impact the quantity of shocks delivered and facilitate optimization of complex ICD programming.
Background
Over the past decade ICD implantation has become
increasingly straightforward, yet ICD programming and
follow up has become more complex due to device feature
and capability enhancements. While sophisticated algo-
rithms provide high sensitivity and improved specificity
of arrhythmia detection, allowing delivery of necessary
effective therapy with minimization of inappropriate defi-
brillation shocks, detection and therapy of ventricular
tachycardia (VT) / ventricular fibrillation (VF) still
requires programming about 100 settings [1-3].
Good programming choices are crucial as they relate to
patient acceptance of ICD therapy. It has been found that
patients who receive multiple shocks have greater diffi-
culty adjusting to the ICD implant. These patients may
become anxious or depressed, especially if a prior history
of these ailments exists [4]. Reducing shocks delivered to
the patient would improve overall patient management.
To date, there is no proven consensus on how to use infor-
mation about the patient's complex diseases to program
the ICD, and usually little is known about the patient's
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spontaneous VT rates, their risk of syncope, or therapies to
effectively terminate spontaneous ventricular arrhyth-
mias. Furthermore, ICD indications have dramatically
changed within the last five years. Physicians may retain
old programming habits even with enhanced devices or
expanding patient indications, which may result in sub-
optimal detection and therapy, such as unnecessary
shocks for faster VT, supraventricular tachycardia (SVT),
and non-sustained VT. Physicians often adjust many pro-
grammable settings that may benefit the patient. For
example, physicians may prescribe patient-specific regi-
mens for anti-tachycardia pacing (ATP) or shock energies
based on lab testing. While one would expect this tailor-
ing of programming to improve outcomes, it has never
been studied.
Empiric programming has been shown to be effective for
subsets of ICD settings, including subsets of dual chamber
detection and ATP therapies [3,5-10]. Whether this holds
true for comprehensive programming of VT/VF detection
and therapy for all ICD patients is unknown.
A proven optimal programming approach would be use-
ful for simplifying therapy prescription, improving ther-
apy outcomes, reducing inadvertent programming errors,
and overall reducing shock-related morbidity. The
EMPIRIC trial has been designed to evaluate a standard-
ized empiric programming regimen by testing the hypoth-
esis stated below. The EMPIRIC trial outcome will provide
an understanding of how programming strategies impact
defibrillation shock delivery in ICD therapy.
EMPIRIC Trial Hypothesis
This trial tests the hypothesis that the shock related mor-
bidity of ICD therapy is similar whether patients are
treated with a standardized empiric programming regi-
men for VT/VF detection and therapy or with a patient-
specific physician tailored approach.
Indices of Shock Morbidity
Only sustained VT/VF that cannot be painlessly termi-
nated should result in shock therapy and it is unusual for
supraventricular arrhythmias (SVT) to require shock ther-
apy. Shock morbidity is related to the number and fre-
quency of shocks that patients receive and therefore
morbidity is reduced if shocks are delivered only when
necessary for effective arrhythmia termination. Thus, indi-
ces that address shock morbidity should reflect both the
frequency and appropriateness of shocks for VT/VF and
SVT.
Shock morbidity is quantifiable by determination of the
following:
♦ proportion of true VT/VF episodes that are shocked
♦ proportion of true SVT episodes that are shocked
♦ time to first shock (VT/VF or SVT)
♦ time to first VT/VF shock
♦ time to first SVT shock
These parameters are used to define the Empiric Trial's
main objectives.
Empiric Trial Objectives
The primary objective is to demonstrate that the propor-
tion of shocked VT/VF episodes and  the proportion of
shocked SVT episodes in a population whose ICDs are
programmed using a standardized regimen for VT/VF
detection and therapy, is either similar to or less than the
same proportion in a similar population whose ICDs are
programmed using a physician-tailored approach. This
primary objective was chosen to independently evaluate
the effects of programming on both appropriate and inap-
propriate ICD shocks (which are likely to have different
implications for patient management). The advantage of
this approach is that it focuses on frequency of shock
delivery while also allowing an assessment of their appro-
priateness. However, this assessment could be con-
founded by a disproportionate number of SVT events in
the two study groups. For example, an abundance of non-
shocked SVT events in the physician-tailored arm, despite
a greater incidence of inappropriate SVT shock therapies
in that arm, nevertheless would result in the proportion of
SVT episodes shocked being similar in the two arms. The
analysis is also heavily dependent on the electrogram data
stored in the ICDs. Given the electrogram storage capabil-
ity of ICDs, differing rates of electrogram storage might
occur between study arms or between VT/VF and SVT epi-
sodes that may skew the amount of data available for
analysis. Therefore, the key secondary endpoint in this
study is considered to be the time to delivery of first shock
therapy in any given patient. This endpoint offers the
advantage that it enables patient cross over to occur
between the study arms without endpoint compromise
and it is a clinically robust indicator of patient shock-
related morbidity. Furthermore, its analysis is not influ-
enced by the appropriateness or otherwise of a shock ther-
apy and therefore cannot be confounded by differential
occurrence of non-shocked SVT events in the study arms.
Other secondary endpoints will further evaluate the
impact of the standardized programming regimen on
patients by an assessment of detection performance,
health care utilization, shock impact on device longevity,
and "true VT/VF" episode durations.Current Controlled Trials in Cardiovascular Medicine 2004, 5:12 http://cvm.controlled-trials.com/content/5/1/12
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EMPIRIC Trial Protocol Design
The EMPIRIC trial is a worldwide, multi-center, prospec-
tive, one-to-one randomized comparison of empiric to
physician tailored programming. About 900 patients were
enrolled worldwide at 52 centers from August 2002 to
October 2003. Each patient will be followed for approxi-
mately one year.
The inclusion criteria require patients to meet all of the
following conditions:
1. Indicated for an ICD according to internationally
accepted criteria.
2. Willing to sign informed consent or offer a legal repre-
sentative who can provide consent.
3. Achieved a 10 Joule safety margin at implant.
Patients are excluded if they:
1. Have permanent atrial fibrillation (AF).
2. Had a previous ICD.
3. Have a medical condition that precludes the testing
required by the protocol or limited trial participation.
4. Have a life expectancy less than one year.
5. Are unable to complete follow-ups at the trial center.
6. Are enrolled or participating in another clinical trial.
Randomization
Patients receiving a Marquis DR ICD are randomized to
one of the two programming approaches after meeting a
10 J safety margin. In order to control for physician prac-
tice between the two treatment arms, randomization is
stratified by treatment center. Further, since the incidence
and prevalence of spontaneous VT/VF and SVT among pri-
mary prevention patients is not well known, randomiza-
tion is also stratified by ICD indication (secondary vs.
primary). A secondary indication includes patients with a
history of spontaneous sustained VT/VF or syncope with
suspected VT. A primary prevention indication includes
all other patients.
Programming Approaches
The physician tailored approach is based on the standard
practice of each physician. All VT/VF programming may
be tailored to the patient except that VT detection must be
turned to 'On' or 'Monitor' to record episodes of slower
VT.
The empiric standardized regimen is based on various
programming strategies to reduce shocks. In this arm, ini-
tial device settings are fixed (see Table 1), with the excep-
tion of the VT detection interval, which can be set slower
than 150 bpm when clinically necessary.
VT/VF detection and therapy programming changes are
permitted at follow-up in both arms only when medically
justified. These changes must be documented, and are
reviewed throughout the study.
Data Collection
Patients are followed for a 12-month period, with
required clinic visits at 3, 6 and 12 months. Data collec-
tion includes: VT/VF and SVT episodes, device program-
ming, medical justifications for VT/VF programming
changes, cardiovascular medication, adverse device
events, P and R wave measurements, and cardiovascular-
related hospitalizations.
Study Design Challenges
A challenge of the study design is the possibility that phy-
sician practice could become biased by in-trial experience,
causing physician practice to gravitate towards the empiric
standardized regimen. This might occur if empiric pro-
gramming is perceived to be efficacious, particularly with
respect to management of rapid ventricular tachycardia by
pace termination. Collection of pre-trial programming
practices provides the capacity to evaluate potential "treat-
Table 1: Empiric Arm Programming
Detection Interval Beats To Detect Redetect Therapies
VF On 300 ms 18/24 9/12 9/12 30 J × 6
FVT via VF 240 ms NA Burst (1 sequence), 30 J × 5
VT On ≥ 400 ms* 16 12 Burst (2), Ramp (1), 20 J, 30 J × 3
SVT Criteria On: AF/Afl, Sinus Tach (1:1 VT-ST Boundary = 66%), SVT Limit = 300 ms
Burst ATP: 8 intervals, R-S1 = 88%, 20 ms decrement
Ramp ATP: 8 intervals, R-S1 = 81%, 10 ms decrementCurrent Controlled Trials in Cardiovascular Medicine 2004, 5:12 http://cvm.controlled-trials.com/content/5/1/12
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ment drift". This result will be reported. Additionally, in
an effort to prevent drifting or possible physician bias to
programming in the physician tailored arm, a weekly
comparison of programming status and initial implant
programming will be assessed through device interroga-
tion information. Any programming changes made must
be supported by a medical justification with a basis of
event-related occurrences (i.e. system- or procedure-
related adverse events, spontaneous episodes, or inappro-
priate shocks). In order to protect protocol design integ-
rity, reprogramming will be encouraged for non-justified
programming deviations. In this manner the initial treat-
ment strategies are tested using an intention-to-treat anal-
ysis with characterization of programming changes.
Empiric Arm Programming Strategies
The empiric arm standardized programming regimen is
based on the following key strategies to reduce shocks.
1) Strategies to reduce shocks for VT/VF
• Multiple ATP attempts for VT≤ 200 bpm: Three sequences
of ATP will be attempted for rhythms with ventricular
rates ≤ 200 bpm. Empiric ATP has been shown to termi-
nate ≥ 90% of VTs in the VT zone [5-10]. Furthermore,
induced VTs do not predict spontaneous VT cycle length,
morphology, or therapy efficacy [11]. Three sequences
will be attempted for rates up to 200 bpm because the
average rate of fast VTs was 199 bpm in the PainFREE Rx1
study, where the FVT zone was 188 – 250 bpm, and more
ATP provided incremental shock reductions[6]. ATP will
be used in all patients because even cardiac arrest patients
have been shown to have VTs [5,12-14].
• ATP for VTs 201 – 250 bpm: One sequence of ATP will
be delivered for fast VTs (FVT) using the FVT via VF zone,
which maintains sensitivity to polymorphic VT (PVT) and
VF and delivers ATP if the 8 beats prior to FVT detection
are ≤ 250 bpm. Approximately 81% of ICD detected VF is
monomorphic VT (MVT). MVT can be pace-terminated
approximately 75% of the time with one sequence of ATP,
without increased risk of syncope or acceleration [6,7,15].
• Longer detection duration: The VF initial beats to detect
will be set to 18 of 24. Shorter beats to detect are often
programmed by physicians, but may increase the unnec-
essary shocks for non-sustained VT and for SVTs. At least
25% of ICD-detected VF is non-sustained VT/VF [15-17].
• High Output 1st VF and FVT Shock: A 30 Joule energy will
be used for the first VF and FVT shock. This will allow
additional time for spontaneous conversions that fre-
quently occur. A higher shock energy may also improve 1st
shock success and therefore reduce the need for multiple
shocks within an episode. The LESS study found no differ-
ence in 1st shock success with 31 J versus DFT++, however
it analyzed all VT/VF faster than 200 bpm [18] ATP should
terminate a majority of these rhythms and for that reason
the benefit of empiric high-energy shocks for polymor-
phic VT (PVT)/VF or after a failed ATP is unknown. The
primary reason some physicians program lower energy 1st
shocks is due to concerns about syncope. Several recent
studies have shown very low syncope rates [6,19] Further-
more, charge times are much faster and more stable over
the life of the device than in older ICDs. For instance, the
Medtronic Marquis DR 30 Joule charge time is 5.9 and 7.5
seconds at beginning and end of life, respectively [20].
2) Strategies to Reduce Shocks for SVTs and Sensing Issues
• Empiric SVT Criteria: The PR logic criteria of AF/A. Flut-
ter and Sinus Tach will be programmed 'On' in all
patients. These criteria have been shown to have a relative
VT/VF sensitivity of 100% and a positive predictive value
to 88.4% [3].
• SVT Criteria applied to faster rates: The SVT limit and VF
rate cut-off will be increased to 200 bpm in all patients to
provide SVT discrimination at faster rates. Two of the top
five reasons for inappropriate detections in the GEM DR
Study (933 patients) were a ventricular rate during AF in
VF zone and a SVT cycle length faster than programmed
SVT limit [3].
• Avoid detecting 1:1 SVTs with Long PRs as VT: 1:1 SVTs
with long PR intervals accounted for 38% of inappropri-
ate detections in the Gem DR (7271) Clinical Study [3]. A
retrospective analysis found that changing the 1:1 VT-ST
boundary programmable parameter from 50% to 66%
might eliminate 32% of all inappropriate detections. The
downside to this approach is that it may result in a 0.8%
rate of VT/VF misclassification or delay [21].
• Longer detection duration: VF initial beats to detect will
be set to 18 of 24. Shorter beats to detect may result in
more unnecessary shocks for SVTs or ventricular over-
sensing.
•  ATP attempts: In addition to terminating ventricular
arrhythmias without shocks, ATP should eliminate some
inappropriate shocks when inappropriate detections
occur by terminating SVTs or slowing conduction.
The VT rate cut-off is one of the most important ICD set-
tings because it can result in untreated symptomatic VT if
set too fast, however it can result in unnecessary therapies
for non-sustained VT, SVTs, or sensing issues, if set too
slow. Reports have shown that some secondary preven-
tion patients have significant symptoms for VTs outside
treated zones [22]. The VT cut-off in the empiric arm is set
to ≤ 150 bpm to err on the side of treating VTs and to
advance the understanding of the incidence of slower VTsCurrent Controlled Trials in Cardiovascular Medicine 2004, 5:12 http://cvm.controlled-trials.com/content/5/1/12
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in all patient populations. The optimal VT rate cut-off may
need to be set according to the patient's presenting condi-
tions at implant (e.g., faster cut-off in primary prevention
patients).
Statistical Considerations
The primary endpoint is the proportion of true episodes
that are shocked during the 12-month follow-up period.
The standardized empiric programming regimen will be
considered non-inferior to the physician tailored pro-
gramming approach if both the proportion of shocked VT/
VF episodes and the proportion of shocked SVT episodes
are no more than 10 percentage points greater in the
empiric arm than the physician tailored arm. The chosen
margin 10 percent is considered clinically important.
It is assumed that 24% of patients will have at least one
true VT/VF episode and 33% of patients will have at least
one true SVT episode during the 12-month follow-up
period. Based on unpublished data from other Medtronic
trials, the within-patient correlation coefficient for multi-
ple episodes is assumed to be 0.3. Assuming a similar dis-
tribution of episode counts per patient as observed in
these previous trials and a shock rate of 30% and 14% for
VT/VF and SVT episodes respectively, a total of 900
patients (450 in each arm) will give at least 80% power for
the VT/VF hypothesis and 90% power for the SVT hypoth-
esis, each tested at the significance level 0.05.
The critical secondary endpoint, time to first shock ther-
apy, will be analyzed using the Cox proportional hazards
model for 1) any VT/VF or SVT, 2) true VT/VF only and 3)
true SVT only. The empiric programming approach will be
considered non-inferior if the upper confidence limit for
the hazard ratio is less than 1.5.
Other Planned Analyses
To better understand the changing ICD patient popula-
tions, we will investigate whether or not the proportion of
appropriate and inappropriate shocks delivered is related
to the following baseline characteristics: main indication
for implant (especially spontaneous sustained monomor-
phic VT), left ventricular ejection fraction, CAD status, his-
tory of Atrial Tach/Atrial Fib/Atrial Flutter, NYHA
classification, use of amiodarone, sotalol, or beta-block-
ers, and inducibility for VT/VF. In addition, to facilitate
understanding of the optimal programmable settings for
various patient sub-groups, we will consider the impact of
programmable settings on outcomes. In particular, we
will examine the "treated cut-off" (TC), which is the VT
detection cut-off if VT detection is 'On' or the VF detection
cut-off if VT detection is 'Off' or 'Monitor'. Outcomes in
patients with a faster TC (physician tailored arm) will be
compared to patients with slower TC (either physician tai-
lored arm or empiric arm). Other programmable settings
that will be investigated include the number of beats to
detect VF and the number of ATP attempts based at vari-
ous rates (e.g., <175 bpm, 175–200 bpm, >200 bpm). The
types of arrhythmias, median ventricular cycle length, and
therapies delivered will also be characterized relative to
the patient's conditions and programming. Furthermore,
the incidence of slower VTs in patients without a history
of spontaneous, sustained monomorphic VT will be
characterized.
Conclusions and Trial Impact
The EMPIRIC trial is a worldwide, multi-center, prospec-
tive, one-to-one randomized comparison of shock-
related morbidity in a population of about 900 ICD
patients whose ICD therapy is determined either by a
standardized programming regimen or by physician tai-
lored programming of VT/VF detection and therapy.
Shock-related morbidity is assessed by a primary objective
that compares between study arms the proportion of VT/
VF episodes that are shocked and the proportion of SVT
episodes that are shocked, and by a key secondary end-
point that compares to time to first shock therapy.
ICD patient populations have rapidly changed within the
last five years but little has been published on optimal
programming for the emerging patient subsets (e.g., pri-
mary prevention). Therefore a standardized regimen of
parameters is used in this trial for all patient populations.
Today's patient population is quite diverse, so a slightly
more sophisticated programming approach may be neces-
sary (e.g. change VT cut-off based on main ICD indica-
tion) or perhaps complex physician tailoring is critical to
reducing shocks.
The EMPIRIC trial will characterize the shock morbidity of
a single empiric programming approach compared to
patient-specific, physician tailored programming. Empiric
programming may be an acceptable strategy if it achieves
equivalence with physician tailored programming. The
EMPIRIC trial results will also provide a better under-
standing of how particular programming strategies impact
the frequency of shocks delivered and will facilitate a way
to optimize complex ICD programming.
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